Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly
24/06/2026 01:10
BRIEF-Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly June 24 (Reuters) - Abbisko Cayman Ltd 2256.HK:
THERAPEUTICS ENTERS STRATEGIC RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH ELI LILLY
ABBISKO THERAPEUTICS AND LILLY TO COLLABORATE ON MULTIPLE INNOVATIVE MEDICINE TARGETS
ABBISKO THERAPEUTICS DEEPENS R+D COLLABORATION WITH LILLY
ELIGIBLE FOR PAYMENTS UP TO US$1.9 BLN UNDER LILLY AGREEMENT
Further company coverage: 2256.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Medicine
See all newsChina's Abbisko jumps on positive clinical trial results for achondroplasia drug
Brief: Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211
Brief: Abbisko Cayman Gets IND Clearance From FDA For Oral Small Molecule Pan-Kras Inhibitor ABSK211
HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration